Q&A: New data further show long-term efficacy of Givlaari for AHP

Alnylam Pharmaceuticals Inc. reported new data from the open-label extension period of the Envision phase 3 study that further demonstrated the long-term therapeutic benefit of Givlaari in patients with acute hepatic porphyria.During the interim analysis of the open-label extension (OLE) period, Givlaari (givosiran) showed maintained efficacy and safety through 12 months of treatment, according to Alnylam’s press release. The company also reported a potential for improved efficacy over time.The purpose of the Envision phase 3 study was to assess the efficacy and safety profile ofRead More

Share on facebook
Share on twitter
Share on linkedin